dc.contributor.author | El-Salhy, Magdy | en_US |
dc.contributor.author | Hausken, Trygve | en_US |
dc.contributor.author | Hatlebakk, Jan Gunnar | en_US |
dc.date.accessioned | 2020-08-11T09:33:03Z | |
dc.date.available | 2020-08-11T09:33:03Z | |
dc.date.issued | 2019-06-24 | |
dc.Published | El-Salhy M, Hausken T, Hatlebakk JG. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients. 2019;11(6):1415 | eng |
dc.identifier.issn | 2072-6643 | |
dc.identifier.uri | https://hdl.handle.net/1956/23646 | |
dc.description.abstract | Background: Faecal microbiome transplantation (FMT) appears to be an effective method for treating irritable bowel syndrome (IBS) patients. However, it is not clear if a high transplant dose and/or repeating FMT are/is needed to ensure a response. The present study was undertaken to clarify this matter. Methods: Ten IBS patients who did not respond to a 30-g transplant subsequently received a 60-g transplant into the duodenum via a gastroscope. The patients provided faecal samples before and 1 month after FMT. They completed five questionnaires measuring symptoms, fatigue and quality of life at baseline and then at 2 weeks, 1 month and 3 months after FMT. The dysbiosis index (DI) was measured using the GA-map Dysbiosis Test®. Results: Seven patients (70%) responded to the 60-g transplant, with significant clinical improvements in the abdominal symptoms, fatigue and quality of life in 57%, 80% and 67% of these patients. The 60-g transplant also reduced the DI. Conclusion: FMT is an effective treatment for IBS. A high-dose transplant and/or repeated FMT increase the response rate and the intensity of the effects of FMT. | en_US |
dc.language.iso | eng | eng |
dc.publisher | MDPI | eng |
dc.rights | Attribution CC BY | eng |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | eng |
dc.title | Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS) | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.date.updated | 2019-12-13T13:23:02Z | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2019 The Authors | |
dc.identifier.doi | https://doi.org/10.3390/nu11061415 | |
dc.identifier.cristin | 1727144 | |
dc.source.journal | Nutrients | |